Working... Menu

N-acetylcysteine for Tobacco Smoking (NACNOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02124525
Recruitment Status : Unknown
Verified April 2014 by Eduardo Salviano Teixeira Prado, Universidade Estadual de Londrina.
Recruitment status was:  Recruiting
First Posted : April 28, 2014
Last Update Posted : April 28, 2014
Information provided by (Responsible Party):
Eduardo Salviano Teixeira Prado, Universidade Estadual de Londrina

Brief Summary:
The purpose of this study is to investigate the efficacy of N-acetylcysteine (NAC) for smoking cessation in a double blind, randomized, placebo-controlled trial. Simultaneously, the study aims to elucidate the role of inflammatory markers and oxidative stress related to nicotine addiction and the use of NAC, an acetylated precursor of cysteine, a naturally occurring amino acid that has antioxidant actions in its own right, in reducing oxidative stress and inflammation in smokers. It will evaluate the use of NAC in smoking cessation, after 4, 8 and 12 weeks of treatment.

Condition or disease Intervention/treatment Phase
Tobacco Smoking Oxidative Stress Inflammation Drug: N-acetylcysteine Phase 3

Detailed Description:

The study will be conducted at the Center of Smoking Cessation, at State University (UEL), in Brazil. A sample of 32 outpatients will be selected, that are refractory to first-line smoking cessation treatment. All patients included in this study under the condition of understanding and signing the informed consent after approval of the research by Ethics Research Committee of UEL. Prior to randomization into the clinical trial, all participants will be assessed with a questionnaire to provide information about demographic, smoking history, nicotine dependence, depressive disorder, anthropometric measurements such as , height, weight, body mass index (BMI), waist circumference (WC), as well as heart rate (HR) and blood pressure (BP).The diagnostic criteria for research for depressive disorder and tobacco use disorder will be assed by trained psychiatrists according to the Structured Clinical Interview. The primary outcome measurement will be the significant reduction on the number of cigarettes/day. Secondary outcome measurements will be: reduction on the exhaled Carbon Monoxide, reduction of Hamilton Depression Rating Scale scores, improvement on Sheehan Quality of Life scale measurements.

The Fagerstrom Test for nicotine dependence (FTND) will be used to assess the severity of tobacco by dependence FTND. The FTND has a scale of six items and the score 0-10. The cutoff point for FTND nicotine dependence will be > 5. The assessment of severity of depression among study participants will be conducted by using Hamilton Depression Rating Scale- 17 items (HDRS). HDRS was translated and adapted for the Brazilian population. Minnesota Nicotine Withdrawal Scale (MNWS) MNWS is a 5-point scale (none, slight, mild, moderate, severe) to measure withdrawal symptoms.The scale assesses the damage that the patient is having due to illness. It is a self - administered scale consisting of 3 items. A score of 0-10 corresponds to the patient's opinion. Assesses the disability damage in three areas: 1) occupational, 2) social life, leisure, 3) family life, activities, and household activities. Can be scored 0-10, 0-3 mild injury, 4-6 moderate damage and 7-10 injury grave.The number of pack-years was calculated according to the definition: the number of cigarettes smoked per day multiplied by number of years smoked and divided by 20 (1 pack has 20 cigarettes).This clinical trial was designed to investigate the efficacy of NAC as a treatment for tobacco use disorder. Data were collected by face-to-face interview at baseline and weeks 4, 8 and 12. Smoking status was also evaluated using exhaled carbon monoxide (COEXH). COEXH was measured using a Micro CO Meter with an electrochemical sensor (Micro CO - Micro Medical Ltd, Rochester, Kent, UK). All participants were instructed to breathe deeply and to hold their breath for 20 seconds and then to exhale slowly and completely through a mouthpiece. Smoking reduction was validated by breath carbon monoxide concentration, and the cut-off point for COEXH levels will be categorized as ≤ 6ppm for smoking cessation (Middleton et al., 2000). Both groups will receive monthly meetings of Group Behavioral Therapy during the course of the study.

Participants (n=32) were randomized into two groups 16 patients in each group, in a double-blind manner to receive NAC or placebo. The dose of NAC was 3000mg/day administered in 500 mg capsules in two daily doses, 3 capsules in the morning and 3 in the evening. The chosen dosage was based on previous studies in which similar dosages had shown to be effective and well tolerated.

Individuals were randomized to NAC or placebo, each group have individuals with equal gender, age, scores of FTND and depressive disorders.

Statistical analysis will be performed with repeated measurements design analyses of variance, and post hoc t test.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Efficacy of N-acetylcysteine as a Cessation Treatment for Tobacco Smoking and Oxidative Stress Reduction
Study Start Date : February 2013
Estimated Primary Completion Date : April 2014
Estimated Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Placebo Comparator: N-acetylcysteine

Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.

Duration: 12 weeks

Drug: N-acetylcysteine
N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
Other Name: N-acetylcysteine 3000mg a day for 12 weeks

Placebo Comparator: Placebo
Placebo will be taken for 12 weeks

Primary Outcome Measures :
  1. The efficacy of N-acetylcysteine in reducing of the cigarettes per day [ Time Frame: At Baseline and after 12 weeks (endpoint) ]
    The primary outcome will be the significant reduction of the cigarettes per day

Secondary Outcome Measures :
  1. Efficacy of N-acetylcysteine in reducing exhaled Carbon Monoxide [ Time Frame: At Baseline and after 12 weeks (endpoint) ]
    The secondary outcomes will be the significant reduction of the exhaled Carbon Monoxide

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Current daily smoker of 10 or more cigarettes per day
  • Capacity to consent to the study and follow its instructions and procedures
  • Female participants will need to be utilizing effective contraception if of childbearing age
  • Must be able to swallow the pills

Exclusion Criteria:

  • Clinically unstable medical or psychiatric disorders that require acute treatment
  • Active gastrointestinal ulcers
  • Pregnancy or breastfeeding
  • Current use of vitamin supplements or other substances with recognized antioxidant action
  • A history of anaphylactic reaction to NAC or any component of the preparation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02124525

Layout table for location contacts
Contact: Eduardo Prado, MD 55-43-9929-1702
Contact: Sandra Nunes, MD 55-43-9801-9111

Layout table for location information
Hospital das Clínicas da Universidade Estadual de Londrina (Londrina State University Clinical Hospital) Recruiting
Londrina, PR, Brazil, 86055-900
Contact: Sinésio Moreire, M.D.    55-43-33714000 ext 5770   
Sub-Investigator: Eduardo Prado, MD         
Principal Investigator: Sandra Nunes, MD PhD         
Sponsors and Collaborators
Universidade Estadual de Londrina
Layout table for investigator information
Principal Investigator: Sandra Nunes, MD, PhD Londrina State University - Center of Smoking Cessation

Layout table for additonal information
Responsible Party: Eduardo Salviano Teixeira Prado, MD, Universidade Estadual de Londrina Identifier: NCT02124525     History of Changes
Other Study ID Numbers: UEL 33553/2011
First Posted: April 28, 2014    Key Record Dates
Last Update Posted: April 28, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Antiviral Agents
Anti-Infective Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs